1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6546B801629C09A8F85256F5E007D9A2B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharma-biotech-alliance-management-success-deal-evaluation-and-negotiation
18
19
2018.215.161.19
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Alliances and Partnerships

Pharma-Biotech Alliance Management Success: Deal Evaluation and Negotiation

DB Image

ID: 4770


Features:

Metrics, Graphics


Pages/Slides: 33


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"Pharma-Biotech Alliance Management Success: Deal Evaluation and Negotiation"


Study Overview
To prosper, pharmaceutical and biotechnology companies must forge strong development and marketing alliances. To do so, business development staff must draw on strong alliance creation skills and tactics. This research will help pharma and biotech business development executives to conduct a gap analysis based by benchmarking their own performance and practices against those at best-in-class companies.


Key topics

  • Strategic Alignment
  • Commitment
  • Communication
  • Negotiation
  • Due Dilligence
  • Cultural Fit

Sample best practices
  • Highlight the relevance of business development assets that you possess to demonstrate a compelling strategic fit.
  • *One company wanted a partner who was able to reach specialists working in emergency rooms and cited this ability as the keystone in its ultimate choice in partners.
  • Choose and empower a designated deal-process manager who can efficiently and honestly navigate negotiation-and-decision milestones to demonstrate seriousness of intent.
  • *An interviewed business development executive chose one pharmaceutical company for an alliance because the point person in charge of the deal showed persistence in getting buy-in from teams within his company and pushed the deal forward “at a pace that small biotechs expect.”
  • Team leaders should not limit or filter communications between teams to ensure high levels of responsiveness.
  • *One executive judged its partner company to have a sluggish pace because the counterpart at the partner company was very slow to respond to requests and created a “bottleneck” effect to communication.

Methodology
This research originated from a Best Practices, LLC consulting project.

Industries Profiled:
Biotech; Pharmaceutical


Companies Profiled:
Atrix; AtheroGenics; Bristol-Myers Squibb; CV Therapeutics; Fujisawa; GlaxoSmithKline; Aderis; Cardiome; Micrologix


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.